These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 24295974)
41. Assessment of Amino Acid/Drug Transporters for Renal Transport of [ Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421 [TBL] [Abstract][Full Text] [Related]
43. OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP. Zhang Y; Ruggiero M; Hagenbuch B Drug Metab Dispos; 2020 Aug; 48(8):622-630. PubMed ID: 32482756 [TBL] [Abstract][Full Text] [Related]
45. Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. Lee HH; Leake BF; Kim RB; Ho RH Mol Pharmacol; 2017 Jan; 91(1):14-24. PubMed ID: 27777271 [TBL] [Abstract][Full Text] [Related]
46. The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters. Cheong J; Halladay JS; Plise E; Sodhi JK; Salphati L Drug Metab Lett; 2017; 11(2):111-118. PubMed ID: 29032766 [TBL] [Abstract][Full Text] [Related]
47. Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395 [TBL] [Abstract][Full Text] [Related]
48. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731 [TBL] [Abstract][Full Text] [Related]
49. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. Jiang R; Dong J; Li X; Du F; Jia W; Xu F; Wang F; Yang J; Niu W; Li C Br J Pharmacol; 2015 Feb; 172(4):1059-73. PubMed ID: 25297453 [TBL] [Abstract][Full Text] [Related]
50. Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates. van der Velden M; Bilos A; van den Heuvel JJMW; Rijpma SR; Hurkmans EGE; Sauerwein RW; Russel FGM; Koenderink JB Malar J; 2017 Oct; 16(1):422. PubMed ID: 29061131 [TBL] [Abstract][Full Text] [Related]
51. Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake. Hove VN; Anderson K; Hayden ER; Pasquariello KZ; Gibson AA; Shen S; Qu J; Jin Y; Miecznikowski JC; Hu S; Sprowl JA Mol Pharmacol; 2022 Jun; 101(6):381-389. PubMed ID: 35383108 [TBL] [Abstract][Full Text] [Related]
52. Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. Jia W; Du F; Liu X; Jiang R; Xu F; Yang J; Li L; Wang F; Olaleye OE; Dong J; Li C Drug Metab Dispos; 2015 May; 43(5):669-78. PubMed ID: 25710938 [TBL] [Abstract][Full Text] [Related]
53. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511 [TBL] [Abstract][Full Text] [Related]
54. In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1. Li L; Song F; Tu M; Wang K; Zhao L; Wu X; Zhou H; Xia Z; Jiang H Int J Pharm; 2014 Apr; 465(1-2):5-10. PubMed ID: 24530383 [TBL] [Abstract][Full Text] [Related]
55. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3. Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247 [TBL] [Abstract][Full Text] [Related]
56. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877 [TBL] [Abstract][Full Text] [Related]
57. Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. Zhang Y; Panfen E; Fancher M; Sinz M; Marathe P; Shen H Mol Pharm; 2019 Jun; 16(6):2342-2353. PubMed ID: 31039308 [TBL] [Abstract][Full Text] [Related]
58. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity. Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322 [TBL] [Abstract][Full Text] [Related]
59. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides. Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Stray KM; Bam RA; Birkus G; Hao J; Lepist EI; Yant SR; Ray AS; Cihlar T Antimicrob Agents Chemother; 2013 Oct; 57(10):4982-9. PubMed ID: 23896476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]